PLAY PODCASTS
Edo Richard and Craig Ritchie: Are Alzheimer's drugs false hope? | Talk to Al Jazeera

Edo Richard and Craig Ritchie: Are Alzheimer's drugs false hope? | Talk to Al Jazeera

Talk to Al Jazeera · Al Jazeera

July 22, 202325m 50s

Audio is streamed directly from the publisher (mgln.ai) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.

Show Notes

Dementia affects 55 million people worldwide, and its most common form, Alzheimer's, accounts for about 70 percent of all cases.

At the Alzheimer's Association International Conference, the largest congress advocating dementia science, held in Amsterdam this month, a pharmaceutical company disclosed details of its trials of a new drug: donanemab.

The American company, Eli Lilly, expects the United States Food and Drug Administration (FDA) to decide by the end of 2023 whether to approve what it is calling a "breakthrough" drug.

But is this medication the best way forward? Or does it just supply cash flow for the pharmaceutical industry?

Leading dementia scientists Edo Richard and Craig Ritchie talk to Al Jazeera.

Subscribe to our channel http://bit.ly/AJSubscribe
Follow us on Twitter https://twitter.com/AJEnglish
Find us on Facebook https://www.facebook.com/aljazeera
Check our website: http://www.aljazeera.com/
Check out our Instagram page: https://www.instagram.com/aljazeeraenglish/

@AljazeeraEnglish
#Aljazeeraenglish
#News

Topics

al jazeera liveal jazeera Englishal JazeeraAl Jazeera EnglishAl Jazeeraaljazeera Englishaljazeera livealjazeera live newsaljazeera latestlatest newsnews headlinesal jazeera videodementiaalzheimer'smedicinesciencedrugsresearchhealthmental healthpharmaceutical companytalk to al jazeeradonanemab